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CHAPTER ONE 
OVERVIEW AND HYPOTHESES 
Misfolded, toxic forms of the amyloid protein, alpha synuclein (α-syn), have been 
implicated in Parkinson’s disease (PD) pathology and have been shown to spread 
throughout the brain in a prion-like manner, explaining the characteristic, progressive loss 
of dopaminergic neurons in PD1–3. A major barrier to identifying targets for more impactful 
treatment of PD is the lack of mechanistic understanding behind this process of α-syn 
propagation. Mechanisms currently being investigated include those behind cellular 
release, uptake, and intracellular processing of α-syn aggregates4. Evidence suggests that 
exogenous α-syn aggregates can enter recipient cells through the endocytic pathway to 
subsequently induce endocytic vesicle rupture, resulting in the cytosolic deposition of 
exogenous α-syn aggregates5–7. More specifically, previous colocalization studies in our 
lab provide evidence that α-syn induced vesicle rupture, labeled by recruitment of 
overexpressed mCherry-Galectin 3 (chGal3) to exposed beta-galactoside sugars located 
exclusively at the site of rupture, occurs mainly at the lysosomal stage of the endocytic 
pathway7.  
Moving forward, we have aimed to corroborate this previous evidence of α-syn  
induced lysosomal rupture, and to investigate the cellular repercussions of this rupture with 
respect to cell death and α-syn transfer. We hypothesized that α-syn aggregates can 
compromise the function of lysosomes, leading to the release of lysosomal contents, 
including key hydrolytic enzymes, into the cytosol. To test this, we have 
immunofluorescently labeled one of the most abundant lysosomal proteolytic enzymes, 
cathepsin B, to analyze the level of lysosomal protease dispersion upon treatment with α-
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syn aggregates in aim 1. Further, we hypothesized that ruptured lysosomes would be 
incapable of resealing after α-syn induced rupture. We have tested this hypothesis in aim 
2 using a triple colocalization analysis between live cell lysosomal markers, labeled α-syn 
aggregates, and chGal3 labeled rupture events. Last, we hypothesized that membrane-
proximal, endocytic lysosomes and autolysosomes may undergo calcium-dependent 
lysosomal exocytosis to release their α-syn contents prior to rupture. In aim 3, we have 
investigated this mechanism of α-syn release by inducing calcium influx while imaging 
membrane proximal lysosomes and their contents through TIRF-M.  
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CHAPTER TWO 
REVIEW OF LITERATURE 
PD Pathology, Symptoms, and Treatments 
The aberrant accumulation of α-syn amyloid structures within the brain is 
increasingly acknowledged as the underlying cause of PD. As α-syn continues to aggregate, 
inclusions are formed within CNS cell bodies or axons that are referred to as Lewy bodies 
(LBs) or Lewy neurites (LNs) respectively, and are the common histopathological feature 
of all synucleinopathies including PD, DLB, and MSA8–13. Advancing α-syn pathology 
leads to the progressive loss of neuronal and glial cell populations through unconfirmed 
mechanisms, giving rise to the distinct neurological symptoms of each synucleopathy14,15. 
Although the involvement of α-syn inclusions is a universal feature of these 
synucleinopathies, each disease within this category is characterized differently and tends 
to involve distinct brain regions, cell types, symptoms, and time courses for disease 
progression. MSA is one of the most distinct synucleinopathies in that it is diagnosed after 
discovery of extensive Lewy body structures within glial tissue, and is characterized by 
massive glial scarring in autonomic centers of the brain, giving rise to many symptoms 
including dysphagia and severe respiratory dysfunction13,16,17. Alternatively, PD is 
characterized by the death of dopaminergic neurons within the Substantia Nigra pars 
compacta (SNpc) of the midbrain, yet Lewy body and Lewy neurite structures can be found 
throughout the CNS18. Further, the intricacies of α-syn pathology in PD patients can vary 
significantly as different brain regions are affected, giving rise not only to the cardinal signs 
of bradykinesia, resting tremor, rigidity, and impaired postural instability, but also an array 
4 
 
   
of secondary symptoms including loss of olfaction and cognitive deficits19,20. The eventual 
spread of pathology throughout cortical areas may explain the high instances of dementia 
known as PDD, which affects approximately 26% of PD patients at initial diagnosis, and 
78% at 8 years after diagnosis21. The characteristics of PDD are similar to those of DLB, 
where cortical areas are the most drastically affected by neuronal death, yet the amyloid 
deposits of α-syn in DLB are much more prevalent and develop throughout the CNS much 
more quickly than those found in patients with PD/PDD22. This may explain why, from the 
time of diagnosis, the average life expectancy in DLB is just 5 years compared to the 9 
year life expectancy after onset of PD23.  
 Current treatments for PD and all synucleinopathies revolve around temporary 
symptom management and do not prevent disease progression through neuronal loss. The 
standard of care for PD includes treatment with L-DOPA, a precursor that can cross the 
BBB and be converted into dopamine by DOPA decarboxylase, thereby enhancing 
neurotransmission from dopaminergic SNpc neurons to the dorsal striatum24. After 
pharmacological treatments begin to fail and produce complications like worsening 
dyskinesia, qualifying PD patients can undergo surgical implantation of an electrode 
stimulator, normally into the subthalamic nucleus, to inhibit abnormal neural activity 
associated with motor dysfunction25. Although deep brain stimulation (DBS) drastically 
improves motor symptoms and life expectancy, eventually, even DBS treatment fails to 
alleviate movement associated symptoms25. More importantly, these treatments have 
limited effect on the non-motor symptoms of PD (cognitive impairment, speech deficits, 
pain, imbalance, etc.), and, for that reason, is currently only indicated as a treatment for 
motor symptoms26. Additional treatments that may become publically available in the near 
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future include grafting of stem cells to replace dying SNpc dopaminergic neurons, although 
this approach also does not address the underlying pathology27.    
Origin of Pathology 
It has been well established that dopaminergic neurons within the SNpc undergo 
selective, accelerated loss in PD, but the explanation for this phenomenon is still largely 
debated. Despite the selective damage to SNpc neurons, aberrant α-syn aggregation is 
commonly thought to originate in other areas of the CNS or possibly the periphery, such 
as the dorsal motor nucleus, glossopharyngeal nerve, vagal nerve, the anterior olfactory 
nucleus, or even the enteric nervous system within the GI tract14,28. Those who accept the 
Braak hypothesis believe that α-syn pathology spreads in a predictable manner throughout 
the CNS, entering the brain through the brainstem from peripheral origination sites14. 
However, the previously mentioned wide spectrum of symptoms associated with PD 
suggests that spreading pathology may be unique in many cases and therefore difficult to 
predict. Various additional patterns of spreading pathology have also been recorded, 
including the observation that LNs are initially larger and more prevalent than LBs.14 
Properties of Alpha Synuclein 
 Synuclein proteins are expressed systemically under normal conditions, but they 
are most abundant within the CNS where they can comprise as much as 1% of the total 
cytosolic protein content29. Within the cytosol, α-syn is localized to the synaptic termini 
and the nuclear envelope, explaining the origin of the name ‘synuclein’30,31. In its free 
cytosolic form, α-syn is soluble, monomeric, and unfolded with no secondary structure, 
although contact with lipid membranes will cause α-syn to adopt an amphipathic alpha 
helical structure, most likely through hydrophobic interactions32. This dichotomy of α-syn 
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structure has led to investigation into the potential role of α-syn in vesicle trafficking; a 
line of thinking that has thus far proved to be accurate. Most notably, a recent study from 
Burré et al suggests that α-syn forms multimers of the helical structure while in contact 
with vesicle membranes, and is essential to the formation of SNARE complex proteins33.  
Alternatively, in states of synucleopathy, α-syn misfolds to form amyloid, 
filamentous structures containing phosphorylated α-syn beta-sheets34–36. Once amyloid 
structures form, they are strongly resistant to degradation by proteinases37. Perplexingly, 
initial misfolding seems to have little genetic influence since the WT form of α-syn is 
involved in 80% of PD cases, which are considered sporadic, while genetic variations 
(SNPs, duplications, and triplications) are known to promote early onset PD in the other 
20% of cases. It has been proposed that particular point mutations may promote formation 
of LBs and LNs by destabilizing the functional helical structure of α-syn, thereby 
increasing the probability of the protein adopting an amyloid structure32. Studies 
investigating duplications and triplications of the SNCA gene, on the other hand, have 
shown that simply overexpressing α-syn will promote development of amyloid 
pathology38,39. Beyond these fairly rare genetic variations in the SNCA gene, age is the 
greatest known risk factor for PD, as is the case for so many neurodegenerative diseases.  
Exogenous Alpha Synuclein Uptake and Vesicle Rupture 
Pathological forms of α-syn have been detected extracellularly (e.g. CSF, plasma) 
in individuals with PD, evidence of α-syn translocation from the cytosol40–42. As these 
extracellular α-syn aggregates come into contact with the external leaflet of recipient cell 
plasma membranes, they are known to induce endocytosis, although the specific 
mechanism of endocytosis remains unknown43. This mechanism of cellular entry is very 
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similar to that of other pathogens, namely adenovirus. In order to fully progress through 
the viral life cycle after endocytosis, adenovirus must escape the endocytic pathway prior 
to degradation within lysosomes. Studies performed by Dr. Chris Wiethoff at Loyola 
suggest that adenovirus effectively evades degradation by inducing endocytic vesicle 
rupture to gain access to the cytosol. Vesicular rupture events in this and other recent 
studies were measured through the overexpression of a fusion protein, mCherry-Galectin 
3 (chGal3)44,45. Cells were transduced to stably overexpress chGal3 based on the affinity 
of the Galectin 3 carbohydrate recognition domain for beta-galactoside sugars present 
exclusively on the extracellular surface, and the topologically equivalent interior leaflet of 
endocytic vesicle membranes46 (Figure #1-i). When vesicle rupture occurs, these sugars 
become exposed to the cytosol where chGal3 is diffusely localized, allowing chGal3 to be 
recruited to form punctuates which can be measured above background fluorescence as 
individual rupture events (Figure #1-ii). 
 
Figure 1. Schematic of the chGal3 labeled rupture system. Overexpressed Cherry-Galectin 3 (chGal3) is 
diffusely localized under normal conditions. After vesicle rupture occurs, chGal3 binds exposed sugars to 
form punctuates. (i) Illustrated depiction of chGal3 re-localization. (ii) Fluorescent images of two different 
neuronal cell types depicting chGal3 re-localization as a result of treatment with α-syn aggregates. 
(ii) (i) 
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Further studies from the Wiethoff lab using this chGal3 assay system suggest that 
induction of vesicle rupture, in the context of adenovirus, is dependent on adenoviral 
protein VI47. Protein VI is thought to induce this membrane rupture by exerting a 
biomechanical tension on the membrane, achieved through interaction between the curved 
N-terminal, amphipathic α-helical structure of the protein and the vesicle membrane47. This 
induced rupture event in the context of adenovirus has been shown to occur more 
frequently at early stages along the endocytic pathway, particularly at the stage of the early 
endosomes44. Using the same assay system for vesicle rupture, we have been able to begin 
characterizing similar rupture events induced by α-syn.  
Just like the adenovirus, α-syn adopts an N-terminal amphipathic α-helical structure 
in association with lipid membranes48–50. Yet, misfolded α-syn does not seem to exhibit the 
same evolutionarily driven, early escape from the endocytic pathway. Instead, our studies 
suggest that α-syn is likely to progress along the endocytic pathway until the inhabited 
vesicle matures to become an acidified lysosome, containing active proteases7. Alpha 
synuclein has been shown to induce rupture preferentially at this lysosomal stage of 
endocytosis7. Moreover, our studies show that α-syn aggregates can progress through the 
endocytic pathway to induce lysosomal rupture within a 24 hour time period7. This would 
not only explain the ability of α-syn to form Lewy body structures in the cytosol of recipient 
cells, but also may explain the ability of α-syn aggregates to induce cell death since 
lysosomal rupture will trigger the release of active proteases which are capable of 
activating pro-apoptotic pathways. Through the quantification of active caspase-3, 
apoptotic activation as a result of vesicle rupture in models of PD has become a major area 
of investigation7,51,52.   
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Figure 2. Model of α-syn induced cell death 
through lysosomal rupture and cathepsin release. 
Cathepsin Dispersion Following Lysosomal Rupture 
The link between endocytic vesicle rupture and caspase-3 related cell death is likely 
to involve dispersion of hydrolytic enzymes from the lysosomal compartment (Figure #2). 
Of the many hydrolytic enzymes contained within the lysosomal lumen, the aspartic and 
cysteine cathepsins, cathepsin D and cathepsin B respectively, are known to be most 
abundant within lysosomes and have also been implicated in the activation of various cell 
death pathways upon aberrant release into the cytosol53–56. 
 
 
 
 
 
 
 
 
 
 Cathepsin D is responsible for activating many of the cysteine cathepsins in the 
acidic environment of the lysosomal lumen, but cathepsin B undergoes autocatalytic 
activation through the cleavage of its own N-terminal propeptide under lysosomal 
conditions57. The subsequent release of active cathepsin B under pathological conditions is 
particularly threatening to intracellular environment due to the unique ability of cathepsin 
B to remain significantly active at neutral pH, especially when bound to naturally occurring 
heparin58,59. Once released, cathepsin B has not only been shown to necrotically degrade 
Cyt-C 
10 
 
   
tissue, but also to activate apoptotic pathways through the cleavage of Bid, a Bcl-2 family 
protein, to form the active ligand, tBid52,53,57,58. After tBid is produced, it can initiate 
downstream activation of the apoptisome. This is accomplished by tBid after allosteric 
activation of Bak, subsequent Bak/Bax oligomerization, and release of Cyt-C through the 
Bak/Bax channel on the outer mitochondrial membrane53. The same oligomerization and 
outcome can also be induced in the opposite manner when cathepsin D is released to 
activate Bax54. Following oligomerization of Bax and Bak, reactive oxygen species are 
released from the mitochondria, ultimately leading to phosphorylation of α-syn at Ser-129 
and subsequent enhancement of α-syn aggregation to form Lewy body structures, although 
the specific kinases involved have yet to be identified34,60,61. This sequence of cellular 
events could explain the currently undescribed pathway of cell death in PD, and could shed 
light on potential mechanisms of α-syn propagation. For these reasons, the localizations of 
both cathepsin D and cathepsin B within models of PD have become a key interest.   
Multiple studies provide compelling evidence that both lysosomal and 
mitochondrial dysfunctions are associated with PD pathology53,60,62–64. We believe that 
cathepsin dispersion due to α-syn induced lysosomal rupture could explain both of these 
implicated types of dysfunction. However, the cellular repercussions of cathepsin release 
can be variable depending on the extent to which cathepsin release occurs55. Lysosomes 
that become moderately permeabilized over time to release small amounts of active 
cathepsins may selectively induce apoptosis through Bax/Bak activation, while full rupture 
of lysosomes to release high concentrations of cathepsins can result in unregulated 
necrosis55. If necrosis is induced in PD, damage would not only occur within the cell of 
pathological origin, but a loss of cell membrane integrity could feasibly enhance the 
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propagation of PD pathology by allowing additional release of α-syn aggregates for uptake 
by neighboring cells. Determining the role of aberrant cathepsin release in the progression 
of PD will be instrumental in the identification of degenerative pathways, mechanisms of 
intercellular propagation, and eventual therapeutic targets. 
Seeding of endogenous alpha synuclein 
 In addition to cathepsin dispersion, exogenous α-syn aggregates can likely be 
released into the cytosol after rupture of the endocytic vesicle. This vesicular escape could 
allow exogenous aggregates to contribute to the formation of LB structures within the 
cytosol by serving as nucleation points not only for other exogenous α-syn aggregates, but 
for endogenous α-syn that has yet to misfold65. This occurrence has been described by 
multiple groups, including Brundin et al, who conducted studies demonstrating that 
endogenously overexpressed human α-syn can transfer from donor to recipient cells in a 
time dependent manner in vitro, and to grafted dopaminergic neurons in animal models to 
seed further formation of LBs and LNs3,65,66. More importantly, this type of transfer  has 
been shown to induce measurable decreases in both viability and striatal fiber density of 
grafted neurons67,68.  
Alpha Synuclein Release 
 The Brundin lab is one of many that have contributed to the extensive repertoire 
of studies supporting the prion hypothesis of α-synuclein propagation.  Additional studies 
from the Seung-Jae Lee lab at Konkuk University have provided evidence of in vitro 
transfer that is enhanced by inhibition of autophagy, while the Kordower lab at Rush 
University has reported transfer upon post-mortem analysis of clinically grafted 
neurons27,69. Although all of these studies provide fantastic evidence that α-syn transfer 
12 
 
   
can occur, very little progress has been made toward understanding the underlying 
mechanisms of α-syn release. Perhaps the only major mechanistic finding to date is that 
standard secretory mechanisms of α-syn release can be ruled out due to persisting release 
after inhibition of secretory vesicle formation by treatment with BFA70. This lack of 
knowledge makes mechanistic study of α-syn release an extremely important, yet 
demanding and unsupported area of study. In order to make progress, pilot studies must 
be performed to investigate feasible alternatives. 
Role of Intracellular Calcium in Alpha Synuclein Transfer 
The process of calcium-dependent exocytosis is extremely well studied and 
normally involves interactions between intracellular vesicles and the inner leaflet of the 
plasma membrane through SNARE protein complex formation71. Secretory and synaptic 
vesicles are guided to target destinations by specific membrane bound Rab GTPases which 
interact with cytoskeletal-associated motor proteins to facilitate transport72. Upon arrival 
at the target site, vesicular SNARE protein interacts with t-SNARE on the inner leaflet of 
the plasma membrane, followed by formation of the full SNARE complex. Once the 
SNARE complex is formed, vesicles are docked and primed, awaiting calcium influx and 
binding to synaptotagmin calcium sensor proteins as the final signal to initiate fusion and 
release of vesicle contents into the extracellular space.  
More recently, it has been established that membrane proximal lysosomes are 
capable of undergoing exocytosis through the same mechanism. In fact, there is evidence 
to suggest that lysosomes are the predominant intracellular vesicle species to undergo 
calcium dependent exocytosis in non-secretory cells, and that all cells utilize lysosomal 
exocytosis for a variety of functions, including membrane repair and cell response to 
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invading pathogens73–76. In lysosomes, exocytosis is facilitated by the calcium sensor, 
synaptotagmin VII, and is has been associated with the release of lysosomal contents into 
the extracellular space58,73,75,77,78. Since lysosomes often contain α-syn aggregates79, the 
tendency for lysosomes to undergo exocytosis in response to calcium influx implicates 
lysosomal exocytosis as a potential release mechanism for α-syn aggregates.  
Misfolded forms of α-syn can be directed into the lumen of lysosomes through 
either the endocytic pathway, if the aggregates are exogenous in origin, or through the 
autophagy-lysosome pathway (ALP) as the cell attempts to sequester and degrade 
increasing levels of aberrant, endogenous aggregates from the cytosol under pathological 
conditions80. Further, α-syn aggregates are known to cause dysfunction within the ALP, 
the consequences of which are enhanced α-syn accumulation within lysosomes and 
increased release of α-syn aggregates from cells69,80. This increased release of α-syn 
aggregates caused by ALP dysfunction has proven to cause cellular consequences, as it has 
been directly linked to increased apoptosis in neighboring cells through the measurement 
of caspase-3 activation69.  
If α-syn is known to accumulate in lysosomes, and cannot be released through 
standard secretory mechanisms, perhaps lysosomal exocytosis is a feasible mechanism of 
propagation. Recent thought-provoking studies have successfully demonstrated a calcium-
dependent release of uncharacterized exosomes containing α-syn, presumably being 
released from cells through the fusion of MVBs with the plasma membrane. Nonetheless, 
somewhat contrasting studies provide evidence to suggest that free aggregates of α-syn are 
also often released into the extracellular space69,81. A possible explanation for this 
collection of findings is the proposed model on page #41, in which lysosomal exocytosis 
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can explain the calcium-dependent release of both vesicular and free α-syn aggregates 
depending on the trafficking of α-syn through the endocytic and autophagy-lysosome 
pathways (Figure #16). 
Using TIRF microscopy, we aimed to determine whether calcium dependent 
lysosomal exocytosis may play a role in α-syn release and propagation. Calcium influx was 
induced by treatment with various ionophores, namely calcium ionophores A23187 and 
calcium ionomycin73,81. We hypothesized that calcium influx would induce lysosomal 
migration and fusion to the PM, resulting in a corresponding increase in visible α-syn 
release from neuronal cell lines in vitro. 
Significance of this Study 
 The significance of our overall study is that it aims to identify novel therapeutic 
targets related to the propagation of pathology in not only PD, but many related 
synucleinopathies. If our findings contribute to an improved understanding of α-syn 
toxicity, intracellular trafficking, and release, then the direction of current research may 
pivot from symptom management approaches to propagation prevention with the potential 
of entirely halting disease progression in relevant synucleinopathies.  
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CHAPTER THREE 
MATERIALS & METHODS 
Cell culture 
The SH-SY5Y human neuroblastoma cell line was acquired from the American 
Type Culture Collection (ATCC). Cells were cultured in Dulbecco's modified Eagle's 
Medium (DMEM) containing phenol red (Invitrogen) and supplemented with 10% fetal 
bovine serum (FBS), 10 ug/ml ciprofloxacin hydrochloride, 1,000 U/ml penicillin, and 
1,000 U/ml streptomycin. For live cell imaging, DMEM lacking phenol red was used, and 
cells were both cultured and imaged in live cell microscopy Delta T Dishes (Bioptechs). 
Overexpression of cherry-galectin 3 
For vesicle rupture experiments, SH-SY5Y cells were transduced to stably 
overexpress chGal3 using a lentiviral viral vector (pLVX) containing the chGal3 gene 
under control of a CMV promoter. To generate lentivirus for transduction, HEK 293T cells 
were transfected using PEI as a transfection reagent with a mixture of equivalent parts 
VSVg, ΔNRF, and pLVX-CMV-chGal3 plasmid. Lentiviral particles were purified 24 
hours post-transfection from conditioned media of 293T cells using a 0.45um Millipore 
syringe. SH-SY5Y cells were then cultured to 80% confluency, treated with the purified 
lentivirus, and spinoculated at 13°C for 2h at 1200 x g. The resulting SH-SY5Y chGal3 
cells were selected using 5 ug/ml puromycin within the previously mentioned culture 
medium.  
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Alpha synuclein aggregation and labeling 
 Full length, recombinant α-syn aggregates for these experiments were generated by 
constant 3-day agitation of purified α-syn monomer in PBS, at a concentration of 5 mg/ml 
and a constant temperature of 37°C82. To prepare aggregates for fluorescence microscopy, 
they were labeled with DyLight™ 488 NHS-ester fluorophores (ThermoFisher). 
Oligomeric structure of aggregated α-syn was confirmed by EM, and was verified to have 
increased molecular weight compared to α-syn monomer by SDS- and native-PAGE. Cells 
in all studies were treated with α-syn aggregates for 24 hours, although concentrations were 
different for specific experiments, varying within the recommended 1ug/ml to 5ug/ml 
range of concentrations normally used for treatment with exogenous aggregates82.  
Immunofluorescent Staining  
 For cathepsin B dispersion experiments, cells were fixed in 0.1 M PIPES 
with 3.7% formaldehyde (Polysciences) at a pH of 6.8 for 20 minutes. Immediately after 
fixation, cells were incubated with one of two polyclonal, rabbit anti-cathepsin B 
antibodies (Abcam at 1ug/ml, or Santa Cruz at 0.5ug/ml), in a PBS solution containing 
10% NDS, 0.1% Saponin, (Sigma-Aldrich) and 0.01% NaN3 for 1.5 hours. After primary 
staining, samples were fluorescently labeled with anti-Rabbit 576-conjugated secondary 
antibody at a concentration of 1:500, and DAPI (1ug/ml) for 20 minutes. Additional 
staining of vesicular antigens in control experiments was done under the same IF protocol 
using 1:400 mouse anti-EEA1 (BD Biosciences) and 1:400 mouse anti-LAMP-2 (BD 
Biosciences) followed by incubation with 1:500 488-conjugated anti-mouse secondary 
antibody (BD Biosciences).  
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Drug-induced vesicle rupture  
 As a positive control for lysosomal rupture and cathepsin B dispersion, cells were 
treated with 10mM LLOMe in DMEM for 1 hour, followed by replacement of drug 
containing media with standard media for a post-treatment incubation period of two hours 
before fixation. Cells were then fixed and stained for cathepsin B according to the above 
immunofluorescence protocol.   
Wide-field fluorescence deconvolution microscopy 
 Immunofluorescence imaging was performed on a DeltaVision microscope 
(Applied Precision) fitted with a 12-bit CoolSNAP HQ digital camera (Photometrics) and 
1.4-numerical aperture 100X objective lens.  
 Live-cell fluorescence images were generated for triple colocalization analysis 
with the same DeltaVision microscope and 100X objective lens, fitted with an alternate 
16-bit Cascade 2 EMCCD digital camera (Photometrics). During imaging, cells were 
maintained within a Weather StationTM chamber at 5% CO2 and 37°C. 
 Resulting images in each study were deconvolved immediately after acquisition 
using the SoftWoRx deconvolution software (Applied Precision). 
 Analysis of deconvolved images 
The analysis of resulting, deconvolved three-dimensional images was carried out 
within the Imaris software package (Bitplane). Surfaces were generated for channels of 
interest, and applied to all collected images using the high-throughput Batch Coordinator 
tool (Bitplane). Multiple parameters from the Batch output were considered, including 
both maximum fluorescence intensity and volume of generated surfaces for 
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colocalization analysis, or overall surface count for the quantification of fluorescent 
puncta abundance between treatment groups for the cathepsin B dispersion study.     
Total internal reflection microscopy 
 To visualize calcium-dependent exocytosis of α-syn aggregates at the membrane of 
human neuronal cells, SH-SY5Y cells were plated onto Fibronectin (Sigma-Aldrich) 
coated 8-well, 1.0 Borosilicate chamber slides (ThermoFisher) and imaged using live cell, 
total internal reflection fluorescence microscopy. A Nikon TIRF microscope equipped with 
an EMCCD iXon 887 camera, computer-controlled automatic filter wheels (Sutter), 1.49 
NA x 100 TIRF-optimized objective, and objective heating element. Labeled α-syn 
aggregates were excited by a 445 nm Argon laser passed through a 488-reflecting dichroic 
mirror optimized for TIRF (Semrock). For most experiments, the stream acquisition 
function of the Metamorph software package was used to take TIRF images focused on the 
bottom membrane of plated cells every 238 ms for an average duration of 180 seconds. In 
select experiments, filter automation was used to image chGal3 and 488-labeled α-syn in 
alternating 0.5 second intervals for an average duration of 180 seconds. Single 
epifluorescent images of the 488-labeled α-syn were taken before and after stream 
acquisition in all experiments. Before and after stream acquisition, chGal3 was excited by 
a Prior Lumen 200 broad spectrum laser, and selectively imaged using a dichroic filter set 
specific to 574nm wavelength emission (Semrock). 
Calcium Influx 
During stream acquisition, calcium ionophores Ionomycin and A23187 were used 
to induce calcium influx in vitro. Plated cells were cultured within 200ul of media just 
before imaging by TIRF-M. During imaging, either 200ul of .5uM Ionomycin was added 
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to yield a .25uM treatment, or 200ul of 5uM A23187 to yield a 2.5uM treatment. Starting 
concentrations for each of these ionophores were determined by review of literature73,81, 
and were further optimized by titrations to reach ideal effect while maintaining cell 
viability.  
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CHAPTER FOUR 
ALPHA SYNUCLEIN INDUCES CATHEPSIN B DISPERSION 
INTRODUCTION 
 Lysosomal dysfunction has been implicated as the physiological mechanism 
behind numerous diseases and is known to negatively impact mitochondrial function in 
addition to other essential functions of the cell, leading to cell damage and loss83,84.  
Further, the majority of diseases related to lysosomal dysfunction are a direct result of 
deficiencies in enzymes within the lysosomal lumen, resulting in toxicity and cell death.84 
Previous findings support the notion that synucleinopathies may lead to the same lysosomal 
enzyme deficiencies through induced lysosomal membrane damage7. If this is the case, 
aberrant forms of α-syn may induce the release of active proteases into the cytosol, a 
process that could be a direct mechanistic explanation of α-syn toxicity. A strong tool for 
the verification of this process in this study has been be the use of known lysosomal 
disruptor, LLOMe, which has been shown to induce cathepsin-dependent cell death as a 
well characterized parallel to α-syn induced lysosomal rupture and cell death85.  
Previous studies have indicated potential cellular repercussions of vesicle rupture 
and subsequent release of active cathepsins, but there is currently no direct evidence of 
cathepsin release in models of PD. We aim to confirm this occurrence in order to 
corroborate our previous findings of lysosomal rupture induced by α-syn, and also to 
further implicate the tBid apoptosis pathway in PD pathology. We hypothesize that samples 
treated with α-syn will have significantly increased lysosomal vesicle rupture events, 
measured by both increased galectin 3 puncta and dissipation of signal from IF labeled 
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Figure 3. Model of cathepsin B 
dispersion within chGal3 expressing 
cells.  
lysosomal proteases (Figure #3). Therefore, we expect to measure decreased Cathepsin B 
puncta in samples treated with α-syn aggregates compared to untreated samples. 
 
 
 
 
 
 
 
EXPERIMENTAL DESIGN 
SH-SY5Y neuroblastoma cells expressing mCherry-Galectin 3 were plated onto 
Fibronectin coated coverslips at a density of 25,000 cells/ml within a 24-well plate and 
allowed to adhere overnight. For plating, cells were initially separated into three groups: 
untreated, α-syn treated, and a negative control for cathepsin B which involved secondary 
antibody staining only. In later trials, a positive control for vesicle rupture was added as a 
fourth sample group, which consisted of 10mM LLOMe treatment. The following day, 
conditioned DMEM was aspirated and replaced with either 500ul of fresh DMEM for 
nontreated control and LLOMe samples, or 500ul fresh DMEM containing 3ug/mL α-syn 
for treated samples and secondary only control samples. After 24 hours of α-syn treatment, 
samples were fixed and stained for cathepsin B. Samples were then mounted to slides with 
FluoromountTM Aqueous Mounting Medium (Sigma-Aldrich), imaged using fluorescence 
deconvolution microscopy, and analyzed for prevalence of cathepsin B puncta. A 
secondary only control was included to confirm specificity of primary antibodies.  
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To determine the legitimacy of cathepsin B staining, a simultaneous IF stain for 
mouse anti-EEA1 and mouse anti-LAMP-2, labeled with subsequent incubation with 488-
conjugated anti-mouse secondary antibody, was performed in conjunction with cathepsin 
B staining to confirm cathepsin B localization to all relevant vesicular compartments. 
RESULTS 
 Early experiments in this series showed promising results in favor of α-syn 
induced cathepsin B dispersion. When chGal3 expressing SH-SY5Y cells were treated 
with 3ug/ml α-syn aggregates, there was an extremely significant decrease in the number 
of detected cathepsin B puncta compared to untreated controls in select trials (Figure #4-
i & iv). Replicate experiments were carried out in the pursuit of additional evidence to 
strengthen our conclusions, and to overcome initial issues with chGal3 signal loss during 
IF staining. In later trials, the duration of the cell fixation protocol was increased from 5 
to 20 minutes, which gave rise to successful retention of chGal3 rupture signal through IF 
staining (Figure #4-ii). However, later trials failed to produce significant dispersion of 
cathepsin B staining, even after multiple replicates were conducted. In an attempt to 
achieve unequivocal cathepsin B dispersion, cells were treated with LLOMe at a 
generous 10 mM concentration. These positive control samples displayed clear and 
extensive rupture (Figure #4-iii), yet failed to produce differences in the prevalence of 
cathepsin B puncta per cell compared to untreated samples, even after several trials 
(Figure #4-v). Due to our interest in cytososolic cathepsin B dispersion as an effector of  
cell viability, we decided to alter our analysis to exclude irrelevant nuclear and 
extracellular cathepsin B signal through the use of image masking in the Imaris software 
package (Bitplane) with the hope that it may unveil a larger margin of difference in 
23 
 
   
cytosolic cathepsin B puncta between treated and untreated samples (Figure #5). 
Although image masking did appear to have this effect to some extent, even these trials 
failed to achieve significance (Figure #4-vi). In a final attempt to determine the fault in 
our experimental design, cells were simultaneously stained for EEA1 and LAMP2 in the 
488nm emission channel, in addition to cathepsin B in the 576nm emission channel, at 
which point it became clear that our cathepsin B stain with different antibodies was not 
colocalizing with known markers of protease containing vesicles, and therefore must be 
producing a non-specific signal (Figure #6). 
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(ii) 
Figure 4. Cathepsin B Dispersion Results (i) chGal3 SH-SY5Y cells (a) Untreated for 24 hours, fixed, and IF stained 
for Cathepsin B. (c) Treated with 3ug/ml of α-syn for 24 hours, fixed and IF stained for Cathepsin B. (e) Repeat of 
(c) without primary antibody staining. Primary staining done with 0.5ug/ml of polyclonal rabbit anti-cathepsin B 
(Santa Cruz), and secondary staining with 1:500 dog anti-rabbit 676. Panels (b), (d), and (f) are duplicate images of 
the preceding column with only Cathepsin B displayed. (ii) Successful retention of chGal3 puncta, displaying 
rupture induced by α-syn in independent channels for chGal3 (a), α-syn (b), cathepsin B (c), and merged (d). (iii) 
LLOMe treated samples induce lysosomal rupture apparent by chGal3 puncta formation. (iv) Quantification of 
Cathepsin B surfaces between treatment groups for a single trial (15 images per group). (v) Common results which 
failed to achieve significance, even with 10 mM LLOMe treatment. (vi) Post masking results from panel (v) 
demonstrate improved significance by masking in select instances. Images are pseudo-colored for optimal 
visualization of specific effects. 
(v) 
(vi) 
(i) 
(iv) 
(iii) 
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Figure 5. Demonstration of the cell masking process for exclusion of nuclear and extracellular 
cathepsin B puncta. Panel A represents raw images before masking. Nuclear puncta were 
excluded by setting cathepsin B staining within DAPI masks to a fluorescence level of zero (B). 
Extracellular cathepsin B staining was excluded by setting puncta outside of chGal3 whole-cell 
masks equal to zero (C). Post masking images (D) were then analyzed for total cytosolic 
cathepsin B puncta using the high-throughput Batch tool of Imaris (Bitplane). 
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Figure 6. Confirmation of non-specific anti-cathepsin B binding. Wild type SH-SY5Y cells were 
plated onto Fibronectin coated coverslips 24 hours prior to fixation. Cells were then IF stained 
with one of two polyclonal, rabbit anti-Cathepsin B antibodies (Abcam at 1ug/ml in panels (a), (b) 
and (c), or Santa Cruz at 0.5ug/ml in panels (d), (e) and (f)). All vesicles that should contain either 
pro-cathepsin B or mature cathepsin-B, including early endosomes, primary lysosomes, and 
secondary lysosomes (endocytic and autophagic), have been immunofluorescently labeled by 
simultaneous IF staining with mouse anti-EEA1 and mouse anti-LAMP2 primary antibodies 
followed by anti-mouse 488 secondary staining. Images were then analyzed for colocalization. 
Images in each row are the same field. The far left column displays Cathepsin B and DAPI. The 
central column displays EEA1/LAMP2 and DAPI. The far right column displays merged images.  
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DISCUSSION 
 Due to the confirmed intraluminal localization of cathepsin B to acidified vesicles 
under normal conditions, cathepsin B signal from IF staining should parallel that of the live 
cell Lysotracker dye which serves as a marker of acidic compartments86,87. Contrary to our 
expectations, however, the resulting puncta from IF staining of cathepsin B was far more 
abundant, had a much smaller than expected size distribution, and was present both 
extracellularly and within the nuclei of stained neuronal cells. Additionally, the results 
from the preliminary experiments of this study indicated a strikingly significant decrease 
in cathepsin B puncta with treatment of α-syn aggregates, despite there being essentially 
no measurable rupture events (chGal3 puncta) to explain the cathepsin B dispersion 
(Figure #4-i). Although secondary only controls were successful (Figure #4-i), these 
uncharacteristic staining patterns prompted further investigation into the binding 
specificity of the anti cathepsin B primary antibodies. Several trials of the experiment were 
repeated adjusting cell fix duration, antibody incubation time, α-synuclein species, and data 
analysis (masking), yet repeat experiments continuously failed to achieve significance. In 
later trials, chGal3 puncta was successfully retained through the IF protocol, most likely 
due to an increase in cell fixation from 5 to 20 minutes, however, overall results of 
cathepsin B dispersion as a result of α-syn treatment never achieved significance in 
triplicate.  
As a positive control for the lysosomal rupture that α-syn aggregates are capable of 
inducing, samples were treated with the peptide drug LLOMe. Initially, samples were 
treated with 1mM LLOMe based on previously published work45, but treatment 
concentration was eventually adjusted to 10mM after titration experiments were conducted 
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to elicit an appropriate effect in our specific cell line. Even the drastically high levels of 
rupture measured in the LLOMe treated samples resulted in no measurable difference in 
cathepsin B puncta, indicating no form of dispersion. At this point in the study, the only 
factor left invalidated was the primary anti-cathepsin B antibodies, which became highly 
suspect for nonspecific binding. To determine conclusively whether the cathepsin B 
staining in this study was legitimate, a simultaneous IF stain for mouse EEA1, LAMP-2, 
and cathepsin B was performed. This control served as final confirmation that the IF signal 
of each of the anti-cathepsin B antibodies used was entirely non-specific and did not 
colocalize with the previously characterized EEA1 or LAMP2 antibody stains as expected. 
These results confirmed that the preliminary measured effect cannot be explained by 
treatment with α-syn, making this aim of our study inconclusive. Due to the certain 
detrimental effects that cathepsin B dispersion could cause within neuronal populations 
(Figure #7), future experiments will be conducted to accurately investigate the effect of α-
syn treatment on lysosomal protease localization. 
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Figure 7. Full model of cathepsin B dependent cell death as a down-stream effect of α-syn induced 
rupture.   
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CHAPTER FIVE 
POST-RUPTURE LYSOSOMAL FUNCTION 
INTRODUCTION 
Understanding the fate of lysosomes after α-syn-induced rupture will be critical to 
understanding intracellular trafficking and propagation of α-syn in synucleinopathies. If 
we can identify the prevalence of various post-rupture lysosomal populations, we can begin 
to confirm details of α-syn toxicity and form more accurate hypotheses about the 
mechanistic details of pathogenic α-syn aggregation and propagation. The primary purpose 
of this study was to determine if lysosomes are completely destroyed by rupture events. If 
lysosomes are completely and permanently ruptured by α-syn aggregates, this would result 
in a complete loss of functional degradation, release of lysosomal contents, and subsequent 
contribution of exogenous α-syn to the formation of cytosolic inclusions. Each of these 
events can contribute to increased strain on remaining cellular degradative pathways over 
time, and can directly promote cell death through activation of previously mentioned 
necrotic or apoptotic pathways. Alternatively, lysosomes may be minimally permeabilized 
in some cases, causing functional loss due to proton leakage without complete release of 
contained α-syn aggregates. If this is the case, these non-functional lysosomes containing 
α-syn may become targets for macroautophagy, resulting in their engulfment to form 
MVB-like structures and subsequent, non-classical release of α-syn by fusion with the 
plasma membrane to secrete exosome-like vesicles of lysosomal origin. Conversely, 
perhaps a significant number of lysosomes are able to reseal following α-syn induced 
rupture, thereby regaining function and maintaining involvement in both degradation of 
31 
 
   
accumulating α-syn aggregates. We hypothesized that the majority of lysosomes would 
rupture to the extent that they permanently lose degradative capacity, indicated by low 
prevalence of lysosomes (Lysotracker positive) that are also positive for the chGal3 rupture 
marker. 
EXPERIMENTAL DESIGN 
The same SH-SY5Y chGal3 cells were plated in 1 mL of DMEM at a density of 
50,000 cells/ml onto Fibronectin coated live-cell Delta T dishes and allowed to adhere 
overnight. The following day, the conditioned media was replaced with 1 mL of fresh 
DMEM containing 3 ug/ml of aggregated and labeled α-syn. In control dishes, the same 
media changes were performed using media lacking α-syn. After 24 hours of treatment 
with α-syn aggregates, dishes washed with fresh DMEM and sequentially treated with 
25nM Lysotracker dye in colorless DMEM for 20 minutes, followed by final replacement 
of media with standard colorless DMEM immediately before imaging. Images were then 
collected using wide field deconvolution microscopy, and analyzed for colocalization on 
the Imaris software package by Bitplane. Control samples undergoing parallel media 
changes, but lacking α-syn treatment, were used to validate the chGal3 rupture system in 
this context. 
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Figure 8. Three dimensional fluorescent images of the colocalization analysis 
process in SH-SY5Y cells. The far left image is a composite of all three channels. 
Middle column displays the indicated, individual channels. The far right column 
displays surface algorithm applied to detect puncta characteristics in each 
independent channel.   
Figure 9. The effect of α-syn treatment on chGal3 labeled rupture events.   
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Figure 10. Triple colocalization data 
graphed by maximum fluorescent 
intensity of chGal3, Lysotracker, and/or 
α-syn signals for (i) Lysotracker surfaces 
(ii) α-syn surfaces and (iii) chGal3 
surfaces. Threshold lines were 
determined by visual determination of 
fluorescent signal above adjacent 
background. Correlation analysis was 
conducted and revealed a significant 
relationship between Alpha synuclein 
intensity and Galectin 3 intensity in 
Lysotracker surfaces (ii), indicating a 
potential for brighter, larger aggregates 
to better induce rupture. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The results of this experiment expand our current understanding of vesicle rupture 
by revealing various existing vesicle populations as exogenous α-syn is processed by the 
cell. The colocalization data above are displayed much like data acquired by FACS, 
although data points represent individual vesicles rather than cells (Figure #10).  
(iii) 
(i) (ii) 
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Alpha synuclein surfaces (Figure #11) represent all surfaces built around α-syn 
puncta. Of these surfaces, the largest portion are positive only for α-syn (mean = 54.3%). 
This population may represent α-syn bound to the extracellular surface, contained within 
early endosomes that have yet to acidify, or α-syn that has ruptured and escaped vesicles 
to exist independently in the cytosol. Conversely, the smallest population of α-syn surfaces 
were double positive for α-syn and chGal3 (α-syn+/chGal3+). This type of colocalization 
between chGal3 and α-syn is most likely to occur through a mutual interaction with the 
vesicle membrane, meaning that the α-syn+/chGal3+ population represents ruptured 
vesicles that have remained bound to α-syn (mean = 8.6%)46,50. Surfaces built around α-
syn puncta that were positive for Lysotracker were fairly prevalent as well (15.7%), 
supporting previous findings that α-syn aggregates are taken up through the endocytic 
pathway where their host endosome can fuse with primary lysosomes79.  Most notably, the 
presence of triple positive population of α-syn surfaces (21.2%) suggests that ruptured α-
syn+/chGal3+ vesicles are likely to be sequestered within acidified compartments through 
unconfirmed mechanisms.   
 
 
Figure 11. Triplicate means of colocalization populations 
within α-syn surfaces. 
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Lysotracker surfaces (Figure #12), on the other hand, represent all intact, low pH 
organelles, which may include a small population of late endosomes and autophagosomes, 
but mainly encompasses primary and secondary lysosomes (ThermoFisher). Surprisingly, 
the most prevalent population of Lysotracker surfaces were triple positive (44.1%), in 
contradiction to our predictions that this population would not exist. Similar to the 
populations from other surfaces, the two double positive populations were the least 
abundant. The population of Lysotracker and α-syn positive surfaces is measured a second 
time here in the context of Lysotracker surfaces rather than α-syn surfaces, and again, 
represents pre-rupture endocytic lysosomes containing α-syn aggregates (19.8%). Vesicles 
double positive for Lysotracker and chGal3 may represent various events. Maybe they arise 
as a result of autophagic uptake of chGal3 positive debris from previous lysosomal rupture. 
Perhaps these Lysotracker and chGal3 positive vesicles occur due to lysosomal reseal after 
rupture, followed by successful degradation of the offending α-syn aggregate. However, 
this population is the least abundant (6.92%), and is therefore less likely to be a main 
outcome in α-syn intracellular trafficking. More certainly, Lysotracker only surfaces 
(29.1%) are likely to represent the pool of primary lysosomes prior to formation of 
secondary lysosomes through fusion with either endosomes or autophagosomes. 
Interestingly, the population distribution of lysosomes from the pool of Lysotracker only 
vesicles appears to vary inversely with the population of triple positive lysosomes between 
trials (Figure #12). 
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Galectin 3 surfaces (Figure #13) mainly represent lysosomal rupture events, and 
a small portion of early endosomal rupture based on previous results7. Of the cumulative 
6,190 rupture events measured between trials (galectin 3 surfaces), a surprising average of 
73.6% of rupture events were also positive for Lysotracker and α-syn. An average of 
20.05% of rupture events were negative for Lysotracker, indicating that a significant 
population of lysosomes at this time point experience rupture which disrupts the low pH 
environment of the lysosome and causes dispersion of the Lysotracker dye. In line with 
common observation from previous surface analysis, the population of Lysotracker/chGal3 
positive vesicles are the least abundant (6.36%). Galectin-3 puncta also underwent 
additional investigation to determine prevalence between untreated and α-syn treated 
samples. It is worth noting that the chGal3 assay system is not perfect, and does produce 
background signal from spontaneous rupture to a small extent in untreated samples. 
However, the results from this analysis demonstrate a substantial increase in chGal3 
Figure 12. Triplicate means of colocalization populations 
within Lysotracker surfaces. 
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labeled rupture induced by α-syn treatment, demonstrating the validity of the assay (Figure 
#9).  
 
 
 
 
 
 
 
These results most importantly raise questions about the population of triple 
positive puncta abundantly present in each of the surface analyses. What do they represent, 
and how are they formed? Could triple positive puncta indicate a potential for lysosomes 
to reseal after rupture, or are ruptured α-syn+/chGal3+ lysosomes rendered non-functional 
and therefore simply targeted for macroautophagy and sequestered back inside of 
independent acidified autolysosomes?  
In order to more accurately address this key question, volumes of α-syn, chGal3, 
and Lysotracker surfaces were analyzed between these different populations. This analysis 
was based on the idea that resealed lysosomes would maintain relatively constant volumes 
within these two surfaces, while triple positive puncta formed through macroautophagic 
uptake of previously ruptured vesicles would likely vary more widely in volume. Volume 
analysis reveals fascinating evidence that the triple positive puncta contain far larger 
volumes of α-syn aggregates and larger volumes of Lysotracker dye compared to single 
Figure 13. Triplicate means of colocalization populations 
within chGal3 surfaces. 
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(iii) 
positive puncta of either marker (Figure #14-i & ii). To supplement this data, maximum 
intensity between colocalization populations was also analyzed (Figure #14-iii). 
 
  
   
 
 
 
 
 
 
 
 
Figure 14. Volume differences between 
four colocalization populations in α-syn 
surfaces (i) and Lysotracker surfaces (ii), and 
maximum fluorescence intensity differences 
between the four colocalization populations 
in α-syn surfaces (iii). All graphs include 
results from triplicate experiments. 
 
(i) (ii) 
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Figure 15. Vesicle outcome map depicting potential pathways for the intracellular trafficking of α-
syn aggregates in a whole-cell context. Initial endocytosis is depicted on the left side. As α-syn 
progresses through the endocytic pathway, the host vesicle acidifies, sequestering acidophilic 
Lysotracker dye to become Lysotracker positive. Double positive lysosomes containing α-syn may 
then successfully degrade α-syn, or rupture to recruit chGal3. Lysosomal rupture may occur 
transiently, allowing lysosomes to reseal (top path), or may result in complete disruption of the 
lysosomal membrane and loss of Lysotracker signal (bottom path). Intact, post-rupture lysosomes 
may continue to function, or may exist as acidic, Lysotracker positive, yet non-functional vesicles 
devoid of necessary proteases, in which case they may undergo lysosomal exocytosis to deposit 
accumulated contents (top). If lysosomes are fully ruptured, however, they may become targets for 
macroautophagy to end up as triple positive species to undergo continued degradation of 
accumulating α-syn, or simply undergo lysosomal exocytosis to release apparent ‘exosome-like’ 
structures from the cell (far right). Lysosomal exocytosis is a calcium dependent process. 
DISCUSSION 
Based on the results of this study and previously published findings, the following 
vesicle outcome map has been generated to predict intermediate phases of intracellular α-
syn trafficking from uptake to release. 
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The path of exogenous α-syn aggregates as they are processed by the cell has 
become considerably more clear based on the results of this study. Initially, α-syn 
aggregates can be seen as independently fluorescent puncta near PM, likely contained 
within early endosomes (Figure). This early-entry population of α-syn is likely to account 
for a large majority of ‘α-syn only’ positive surfaces (Figure #11). The exact 
mechanisms of uptake remain to be elucidated, but our detection of double positive α-syn 
and Lysotracker vesicles  serves as substantial evidence, in agreement with previous 
findings, that α-syn is taken up through the endocytic pathway to be contained within 
endocytic lysosomes79.  
Once the α-syn aggregates are internalized, the mechanism in which they gain 
access to the cytosol has been widely debated4. Although our data does not specifically 
highlight temporal aspects of intracellular α-syn trafficking, it does strongly corroborate 
our previous findings and hypothesis that vesicle rupture is the mechanism of cytosolic 
entry for exogenous α-syn aggregates7. If rupture does occur later in the endocytic 
pathway at the stage of endocytic lysosomes, as per our previous findings7, then it can be 
said that the chGal3 surfaces predominantly represent ruptured lysosomes. Under this 
assumption, our chGal3 data indicates that at least 20.05% of rupture events induced by 
α-syn cause dissipation of Lysotracker signal, indicating severe disruption of the 
lysosomal membrane leading to the dissipation of luminal contents. In each of these 
cases, α-syn is likely to be exposed in the cytosol with the potential to interact with other 
exogenous aggregates and act as a template for misfolding of endogenous α-syn, 
ultimately explaining the ability of exogenous aggregates to contribute to the 
development of toxic LB and LN structures3,65,66. Furthermore, the subset of rupture 
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events that are positive for chGal3 alone (6.05%) represent potential for complete release 
of free α-syn aggregates from ruptured vesicles into the cytosol to induce the same, 
unhindered nucleation effect.  
In fact, it is possible that a much larger population of rupture events causes 
complete destruction of lysosomes, depending on the origin of triple positive puncta. 
There are two possible outcomes for ruptured lysosomes that could give rise to the triple 
positive vesicles observed in this study. First, lysosomes may remain independently 
functional after transient permeabilization, retention of α-syn aggregates, and recruitment 
of chGal3. However, if this were the case, the overall volume of triple positive vesicles 
would be likely remain constant, making primary lysosomes (Lysotracker only) the same 
size as triple positive vesicles. Based on our volume analysis of both α-syn and 
Lysotracker surfaces, we can confidently say that this is not always the case. A 
significant population of triple positive puncta contain much larger volumes of α-syn 
aggregates than α-syn aggregates in pre-ruptured lysosomes (means = 1.261 µm3 vs 
0.3092 µm3, respectively), with higher fluorescence intensities (Figure #14-i & iii). 
Additional analysis of Lysotracker surface volumes reveals the same pattern of increased 
volume for triple positive puncta compared to Lysotracker only, primary lysosomes 
(means = 1.045 µm3 vs 0.5028 µm3) (Figure #14-ii), reflecting the known volume 
differences between primary lysosomes and autolysosomes (lysosome volume range: up 
to 0.065 µm3, autolysosome volume range: up to several µm3 )88,89. These results strongly 
suggest that triple positive vesicles can be formed by cumulative recruitment of ruptured 
α-syn+/chGal3+ lysosomes to distinct intact lysosomes, which, through known 
mechanisms, could only be explained by macroautophagy. Uptake of these ruptured 
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lysosomes is also likely to be occurring at a rate which exceeds the degradative capacity 
of the autolysosomes, especially under these conditions of lysosomal dysfunction. This 
indicates that a significant portion of the triple positive puncta also include previous, fully 
ruptured lysosomes, meaning that the frequency of complete lysosomal destruction by α-
syn is certainly larger than the mentioned 20.05%. Of course, this large scale occurrence 
of lysosomal destruction would have extremely detrimental effects on neuronal 
populations in vivo.  
In support of our findings, the Yoshimori lab at the University of Osaka recently 
demonstrated the concept that damaged lysosomes can become targets for autophagy45.  
Evidence from their study suggests that lysosomal rupture induces upregulation in 
autophagy, allowing the clearance of ruptured lysosomes. However, in cells deficient of 
essential autophagic proteins, clearance of these ruptured lysosomes was fully 
attenuated45. These findings, in congruence with our own, lead us to the conclusion that 
the majority of ruptured lysosomes are not simply resealing after rupture, but instead are 
being taken up, and accumulating within distinct lysosomal compartments through 
macroautophagic mechanisms. 
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CHAPTER SIX 
CALCIUM-DEPENDENT RELEASE OF α-SYNUCLEIN 
INTRODUCTION 
 Thus far, this study has shed light on mechanisms of uptake and intracellular 
processing of exogenous α-syn aggregates, but has yet to address the mechanisms behind 
well documented α-syn release and intercellular propagation. If exogenous α-syn 
aggregates do progress through the cell, inducing lysosomal rupture, and eventually 
becoming secondarily sequestered within autolysosomes, then how can previous findings 
of α-syn release from cells be explained?  
It has been determined that α-syn aggregates can be released from cells in a calcium 
dependent manner in apparent vesicular fractions that have been referred to as exosomes81. 
Beyond this, compelling evidence from multiple studies suggests that lysosomal exocytosis 
occurs in response to calcium influx, especially in response to the membrane damage73,76. 
We hypothesize that under conditions of drastic ALP dysfunction, as is the case during 
accumulation of aberrant α-syn, lysosomes will be unable to properly degrade α-syn 
aggregates, and will therefore accumulate α-syn aggregates that may be released to the 
extracellular space through mechanisms of calcium-induced lysosomal exocytosis. 
Understanding whether known mechanisms of lysosomal exocytosis contribute to the 
propagation of toxic forms of α-syn could reveal important drug targets for therapeutic 
intervention. If lysosomal exocytosis is a predominant form of α-syn propagation, selective 
inhibition of this process in cells containing aberrant forms of α-syn aggregates may 
become an avenue of further investigation. 
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EXPERIMENTAL DESIGN 
ChGal3 expressing SH-SY5Y cells were plated onto Fibronectin coated 
borosilicate chamber slides and allowed to adhere overnight. To image lysosomes in this 
context, cells were treated with 200ul of 1 uM LysoSensor™ Green DND-189 
(ThermoFisher) in DMEM for 30 minutes prior to imaging. As per product protocol, cells 
remained cultured in LysoSensor™ containing media during imaging. For visualization of 
α-syn release, DMEM containing 3ug/ml of DyLight™ 488 labeled α-syn aggregates was 
then added to each well of the chamber slides for 24 hour treatment period. After α-syn 
treatment, media will be replaced with 200ul of fresh DMEM in each well, and cells will 
be imaged by TIRF microscopy. During imaging, calcium ionophores (Ionomycin or Ca2+ 
Ionophore A23187) will be added within 200ul of DMEM to initiate calcium influx. 
Cellular response to calcium influx will be measured by appearance of labeled α-syn, 
lysosomes, and galectin3 puncta to the basal plasma membrane. Fluorescence intensity 
over time will then be evaluated to identify fusion events of either individual lysosomes or 
MVBs. 
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RESULTS 
For this preliminary study, TIRF microscopy was only achieved within the 488nm 
fluorescence emission channel due to limitations of available live cell lysosomal dyes and 
compatible fluorescence microscopy filters. For this reason, rather than looking at α-syn 
aggregates and lysosomal markers simultaneously, we attempted to first confirm our ability 
to induce calcium-dependent lysosomal exocytosis as seen in Simon et al73. Rather than 
expressing fluorophore conjugated lysosomal antigens, we attempted to label lysosomes 
using the only available live cell lysosomal marker available in the channel in which we 
could appropriately image using TIRF, LysoSensor™ Green DND-189 (ThermoFisher). 
The LysoSensor stain was fairly successful for visualization of endogenous acidified 
compartments by epifluorescence (Figure #17), but unfortunately produced significant 
staining of the plasma membrane that prevented proper visualization of lysosomal 
compartments while imaging by TIRF (Figure #18).  
 
Figure 16. LysoSensor Staining visualized by 
epifluorescent excitation. Acidified vesicles 
can be distinguished 
Figure 17. LysoSensor Staining visualized by 
TIRF excitation. Acidified vesicles cannot be 
distinguished through basal membrane 
staining. 
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Despite this limitation of the LysoSensorTM stain, the possibility of direct 
visualization of calcium dependent α-syn release was still of key interest to us, especially 
as preliminary evidence to justify further study in this vein. During initial imaging of 
DyLight™ 488-labeled α-syn aggregates, a drastic increase  in fluorescence intensity was 
measured at numerous points within the imaged field immediately following induced 
calcium influx (Figure #19). This may indicate calcium dependent migration of vesicular 
α-syn aggregates, likely contained within lysosomes and/or autolysosomes, to the plasma 
membrane. In some specific regions of interest, patterns of fluorescence dissipation that 
would be expected to occur during vesicular fusion events were measured (Figure #20).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18. Demonstration of calcium-dependent α-syn release. 
Total internal reflection fluorescence image of chGal3 SH-SY5Y cells 
treated with α-syn aggregates for 24 hours at (a) time zero, before 
addition of calcium ionophore and (b) time 30 sec, after addition of 
calcium ionophore. Images in panels a and b are excited by 488 
channel laser only. (c) Image of chGal3 localization with red laser 
excitation only. (d) Graph of mean fluorescence intensity over time 
for the color coated regions indicated by boxes in panels a and b. 
 
 
a b 
c d 
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However, some puncta are much larger, brighter, and appear to remain more highly 
fluorescent over time, as indicated in Figure #19 by the green box and corresponding 
fluorescence intensity graph. We suspect that this type of change in fluorescence over time 
is indicative of a MVB-like structure, likely an autolysosome containing α-syn and debris 
from previously ruptured vesicles, fusing with the PM to release both soluble and vesicular 
fractions. The majority of α-syn puncta that migrate to the PM in response to calcium influx 
appear to do so transiently. An example of this is depicted by the blue box and 
corresponding fluorescence intensity graph in Figure #19, where the punctate α-syn 
approaches the membrane and quickly returns to baseline intensity. This could indicate 
fusion of individual lysosomes to the PM, allowing release of primarily soluble contents 
into the extracellular space, resulting in a decrease of fluorescence intensity back to 
baseline. 
 
 
Figure 19. Potential release of α-syn by lysosomal exocytosis. (a) Full imaging field taken by TIRF-M.  
Multiple SH-SY5Y cells can be seen containing 488-labeled α-syn aggregates. (b-g) Enlarged region of 
interest from panel (a) displaying a potential fusion event in 1 second intervals after calcium influx. 
 
 
a b c d 
e f g 
48 
 
   
DISCUSSION 
 Although the results of this preliminary study parallel those of lysosomal 
exocytosis in Simon et al73, our findings were less profound. Based on the abundant 
localization of α-syn aggregates to lysosomal compartments demonstrated in this study 
and previously published studies79, in conjunction with the abundant lysosomal 
exocytosis reported in Simon et al, we expected to visualize substantial release of α-syn 
aggregates in response to induced calcium influx. However, apparent fusion events were 
exceedingly rare. Our results raise questions about the factors that may influence cellular 
capacity for lysosomal exocytosis between different cell types.  
Factors that may influence lysosomal exocytosis 
  It has been strongly established that vesicles equipped with SNARE complex 
proteins that are capable of calcium-dependent exocytosis exist in distinct pools localized 
to different cellular regions. So called ‘fast’ phase exocytosis occurs through the fusion of 
of vesicles proximal to inner leaflet of the plasma membrane that are docked and primed 
for fusion, awaiting calcium influx for final initiation of exocytosis90. More recently it has 
been demonstrated that lysosomes localize to distinct cellular regions much like secretory 
vesicles, with membrane proximal lysosomes being most capable of fast phase calcium-
dependent exocytosis73,91. However, vesicles destined for exocytosis must first be recruited 
to the membrane from intracellular pools, the driving force for which is kinesin and myosin 
motor activity along microtubules and actin respectively90. However, efficient trafficking 
of lysosomes to the membrane for exocytosis is dependent on multiple factors, including 
cortical actin, calcium channel expression, cholesterol, and clatherin adaptor proteins 
essential for SNARE protein targeting78. These factors influencing lysosomal exocytosis 
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are likely to vary in function and prevalence between cell types, making it feasible that 
studies exhibiting efficient calcium dependent exocytosis in various non-neuronal cell 
types may not translate directly to the neuronal cell lines used in this study. Perhaps the 
use of primary dopaminergic neurons from the SNpc, which express specific Cav1.3 
calcium channels known for their higher calcium conductance during hyperpolarization, 
would better exhibit lysosomal exocytosis and measurable release of α-syn aggregates92. 
Furthermore, studies like ours that involve α-syn aggregate treatment add an additional 
layer of complexity. This is partially due to the ability of α-syn to alter the structural 
dynamics of actin, potentially inhibiting standard vesicular trafficking, and possibly even 
stabilizing cortical actin to physically hinder lysosomal access to the plasma membrane93. 
Ultimately, it is clear that our experimental approach to this mechanistic study of α-syn 
release will need to be refined substantially before accurate conclusions can be drawn. 
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CHAPTER SEVEN 
CONCLUSIONS AND FUTURE DIRECTIONS  
Although aspects of our study failed to produce conclusive evidence, there are 
multiple components of the colocalization analysis in aim 2 that justify novel and 
interesting conclusions with respect to the intracellular trafficking of exogenous α-syn 
aggregates. First, this study builds on the largely debated previous evidence in favor of α-
syn rupture as the mechanism of exogenous α-syn entry into the cytosol. Additionally, this 
study provides the first evidence suggesting that exogenous α-syn aggregates eventually 
accumulate within autolysosomes, along with overexpressed chGal3, after inducing 
rupture of endocytic vesicles. This conclusion is strongly supported by results of abundant 
and drastically enlarged triple positive puncta in our colocalization study, indicative of 
acidified vesicles containing cumulatively recruited α-syn+/chGal3+ ruptured vesicles that 
may only be explained by mechanisms of macroautophagy. Moreover, accumulation 
within autolysosomes suggests that these degradative compartments are incapable of 
clearing accumulating α-syn. This could be a result of excessive treatment with α-syn 
aggregates, but is also likely to reflect ALP dysfunction. If α-syn is truly accumulating 
within autolysosomes as a result of dysfunction, then lysosomal exocytosis remains a key 
mechanism of α-syn release as a last line of defense by the cell. 
 Despite the lack of direct evidence of cathepsin B dispersion in this study, our 
model of cathepsin B dependent cell death after α-syn induced vesicle rupture is 
strengthened by this study. Based on our colocalization results, we can speculate that 
lysosomal disruption is occurring to the extent that substantial cathepsin release is 
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occurring, resulting in unregulated necrosis55. Perhaps in cases of PD, especially in early 
pathology, cells experience occasional, full rupture of lysosomes, causing release of 
cathepsin B and D to cause mild disruption of surrounding structures, mitochondrial 
permeabilization, and subsequent release of both Cyt-C and ROS. In later stages of PD 
when pathological forms of α-syn are more abundant, however, cell death may occur more 
rapidly through mechanisms of necrosis as a result of increased cathepsin release consistent 
with our results of drastic lysosomal rupture. Particularly in synucleinopathies with much 
faster disease progression and vastly more abundant synuclein inclusions, like DLB, 
perhaps unregulated necrosis of neural tissue is the predominant form of cell death as active 
cathepsins degrade essential proteins and cause widespread disturbances throughout the 
cell. In the future, confirmation of cathepsin B and D dispersion upon α-syn aggregate 
treatment will play an important role in confirming or disproving our hypothesis of α-syn 
toxicity.  
FUTURE DIRECTIONS 
In addition to pursuing conclusive results for our unresolved aims, many studies 
in the field of PD research have sparked our interest in beginning more expansive studies. 
To start, the Jankovic lab at the Baylor College of Medicine has published interesting and 
relevant results of autophagic function in the presence of mutant forms of α-syn 
aggregates. Their results suggest that some mutant forms of α-syn can strongly bind the 
lysosomal membrane antigen, lamp2a, to prevent fusion of autophagosomes to 
lysosomes, thereby inhibiting macroautophagy94. We believe this effect may be exclusive 
to particular mutant forms of α-syn, in which case, our results suggesting successful 
autolysosome formation in the presence of WT α-syn aggregates still stand, although 
functional degradation may be inhibited due to saturation of the ALP pathway and 
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resulting strain on degradative machinery. Future studies investigating the ability of WT 
α-syn aggregates to bind lamp2a, however, may be warranted to verify our findings.  
 We also plan to further investigate cell response to α-syn treatment from the 
perspective of lysosomal synthesis. Evidence from the Björklund lab at Lund University 
suggests the lysosomal synthesis regulator, TFEB, is capable of enhancing autophagy 
when overexpressed to reduce pathological features of PD in rat models and ex-vivo 
human PD midbrains. The reverse effect was seen in TFEB deficient samples, in which 
neurotoxicity was increased. We would like to build upon these finding by investigating 
the effect of TFEB overexpression on α-syn intracellular trafficking, release, and chGal3 
labeled rupture.  
 Eventually, we also hope to expand upon the chGal3 rupture assay by investigating 
the potential role of Galectin-3 in cellular recognition of, and response to, α-syn induced 
vesicle rupture. It has been determined that Galectin-3 plays a major role in inflammation 
and immunity95. Observations of Galectin-3 release from cells, and co-involvement in α-
syn induced microglia activation have also been reported96. For these reasons, we suspect 
that there is likely an evolutionary reason for endogenous Galectin-3 to possess a C-
terminal carbohydrate recognition domain capable of inducing relocalization of Galectin-
3 to sites of vesicle rupture. Perhaps Galectin-3 is essential for the activation of  the 
numerous neuroinflammatory changes that are activated in PD to induce toxicity97. We are 
anxious to conduct studies in the future investigating Galectin-3 as a component of LB and 
LN structures, contributor to α-syn toxicity, and even effector of α-syn release. 
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